UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2024
Commission File Number 001-41923
EUPRAXIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
N/A
(Translation of Registrant’s name)
201-2067 Cadboro Bay Road
Victoria, British Columbia, Canada V8R 5G4
Telephone: (250) 590-3968
(Address and telephone number of registrant’s
principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☐ Form
40-F ☒
DOCUMENTS INCLUDED AS PART OF THIS REPORT
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Eupraxia Pharmaceuticals Inc.
|
Date: May 22,
2024 |
|
|
|
By: |
|
/s/ Bruce Cousins |
|
|
|
|
|
|
Name: Bruce Cousins |
|
|
|
|
|
|
Title: President and Chief Financial Officer |
Exhibit 99.1
Eupraxia Pharmaceuticals to Host Virtual KOL
Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis (“EoE”) on May 29, 2024
VICTORIA, BC, May 22, 2024 - Eupraxia
Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company
leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today
announced that it will host a virtual key opinion leader (“KOL”) event on Wednesday, May 29, 2024, at 10:00 AM ET.
To register, please click here.
The event will feature Evan S. Dellon, MD, MPH
(University of North Carolina School of Medicine) who will join Company management to discuss the unmet medical need and current treatment
landscape for EoE. Dr. Dellon is Chairman of the Company’s Gastrointestinal Clinical Advisory Board.
The KOL event will focus on data from the Phase
1b/2a RESOLVE clinical trial and highlight clinical development plans evaluating EP-104GI for the treatment of EoE.
Utilizing the Company’s proprietary DiffuSphere™
technology, EP-104GI has shown the potential to target drug delivery to the esophageal tissue and improve treatment outcomes for the EoE
patient population.
A live question-and-answer session will follow
the formal presentation.
About Evan S. Dellon, MD, MPH
Evan S. Dellon, MD, MPH, is a Professor of Medicine
and Adjunct Professor of Epidemiology at the University of North Carolina School of Medicine in Chapel Hill. Dr. Dellon received his undergraduate
degree from Brown University and his medical degree from Johns Hopkins School of Medicine. He completed internship and residency in Internal
Medicine at Massachusetts General Hospital. He performed a clinical and a research fellowship in Adult Gastroenterology at UNC, during
which he also received a Masters of Public Health degree in Epidemiology from the UNC School of Public Health. Dr. Dellon is currently
the Director of the UNC Center for Esophageal Diseases and Swallowing (CEDAS) and has served as an Associate Editor for Clinical Gastroenterology
and Hepatology. Dr. Dellon’s main research interest is in the epidemiology, pathogenesis, diagnosis, treatment, and outcomes of
EoE and the eosinophilic gastrointestinal diseases (“EGIDs”). The goal of his research is to improve the lives of patients
with EoE and EGIDs by learning how to better diagnose, treat, and monitor these conditions.
About Eosinophilic Esophagitis (EoE)
EoE is an inflammatory-mediated disease in which
white blood cells migrate into and become trapped in the esophagus, creating pain and difficulty with swallowing food. According to market
research from Clearview, EoE affects more than 450,000 people in the United States and has been identified by the American Gastroenterological
Association as rapidly increasing in both incidence and prevalence. Impacts from both symptoms and interventions frequently lead to mental
health issues, compounding the disease burden of EoE for both the health care system and the individual.
About Eupraxia Pharmaceuticals Inc.
Eupraxia is a clinical-stage biotechnology company
focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high
unmet medical need. The Company strives to provide improved patient benefit and has developed technology designed to deliver targeted,
long-lasting activity with fewer side effects. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to
facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tuneable pharmacokinetic (PK) profiles.
This investigational technology can be engineered for use with multiple active pharmaceutical ingredients and delivery methods.
Eupraxia recently completed a Phase 2b clinical
trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to osteoarthritis of the knee. The trial met its primary endpoint and three
of the four secondary endpoints. Eupraxia has expanded the EP-104 platform into gastrointestinal disease with the Phase 1b/2a RESOLVE
trial for treating eosinophilic esophagitis. Eupraxia is also developing a pipeline of later- and earlier-stage long-acting formulations.
Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the
activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.
Notice Regarding Forward-looking Statements
and Information
This news release includes forward-looking statements
and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can
be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled",
"intends", "contemplates", "anticipates", "believes", "proposes", "potential"
or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results
"may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward looking
statements in this news release include statements regarding the details of the Company's virtual KOL event; the Company's product candidates,
including expected benefits to patients; the results gathered from studies and trials of Eupraxia's product candidates; the potential
for the Company's technology to impact the drug delivery process; and potential pipeline indications. Such statements and information
are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research
and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect
to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities,
including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes
that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events
and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known
and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's
limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements
under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that
are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor;
the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval,
which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals
for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of our product
candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects
or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services;
the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may
not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available;
any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely
affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics
on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and
uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties
described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to
identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking
statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated
or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking
statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or
revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.
SOURCE Eupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Historical Stock Chart
From Jul 2023 to Jul 2024